Amgen Inc. (AMGN) launches AmgenNow, a direct-to-patient program beginning with Repatha. Repatha reduces cardiovascular risks, offered at $239/month, 60% lower than the current list price, supporting the Trump Administration’s aim to lower drug costs for Americans.

Amgen Inc. (AMGN) announces a $650 million expansion of its US manufacturing network, enhancing drug production at its biologics facility in Juncos. This expansion reinforces the company’s commitment to US biomanufacturing and global supply chain resilience.

Aristotle Capital Management, LLC, reports Amgen Inc. (AMGN) as a significant detractor in Q2. Despite concerns about tariffs, tax reform, and drug pricing, Amgen showed growth in Repatha, Evenity, and Prolia sales. The company plans a $2 billion expansion in Ohio and North Carolina, emphasizing innovation and commitment to domestic manufacturing.

Read more at Yahoo Finance: Amgen (AMGN) Announces Launch of AmgenNow